Siglec-E is up-regulated and phosphorylated following lipopolysaccharide stimulation in order to limit TLR-driven cytokine production

Journal of Immunology

Volumn 183, Issue 12, 2009, Pages 7703-7709

  Boyd, Caroline R ^a   Orr, Selinda J ^a,c   Spence, Shaun ^a   Burrows, James F ^a   Elliott, Joanne ^a   Carroll, Helen P ^a   Brennan, Kiva ^b   Gabhann, Joan Ní ^b   Coulter, Wilson A ^a   Johnston, James A ^a   Jefferies, Caroline A ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LECTIN RECEPTOR; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN TYROSINE PHOSPHATASE SHP 2; RANTES; SIGLEC E; TOLL LIKE RECEPTOR; TYROSINE; UNCLASSIFIED DRUG; B LYMPHOCYTE ANTIGEN; CYTOKINE; LEUKOCYTE ANTIGEN; MYD88 PROTEIN, MOUSE; PTPN11 PROTEIN, MOUSE; SIGLEC E ANTIGEN, MOUSE; SIGLEC-E ANTIGEN, MOUSE; TICAM 1 PROTEIN, MOUSE; TICAM-1 PROTEIN, MOUSE; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ENZYME INHIBITION; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; UPREGULATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; DOWN REGULATION; DRUG ANTAGONISM; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CELL LINE; CELL LINE, TRANSFORMED; CYTOKINES; DOWN-REGULATION; HUMANS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; UP-REGULATION;

EID: 76249093445     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902780     Document Type: Article

References (34)

1. Liu, A. H. 2008. Innate microbial sensors and their relevance to allergy. J. Allergy Clin. Immunol. 122: 846-858; quiz 858-860.
2. Kenny, E. F., and L. A. O'Neill. 2008. Signalling adaptors used by Toll-like receptors: an update. Cytokine 43: 342-349.
3. Kobayashi, K., L. D. Hernandez, J. E. Galan, C. A. Janeway, Jr., R. Medzhitov, and R. A. Flavell. 2002. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110: 191-202. (Pubitemid 34876547)
4. Burns, K., S. Janssens, B. Brissoni, N. Olivos, R. Beyaert, and J. Tschopp. 2003. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med. 197: 263-268. (Pubitemid 36152320)
5. Shi, M., W. Deng, E. Bi, K. Mao, Y. Ji, G. Lin, X. Wu, Z. Tao, Z. Li, X. Cai, et al. 2008. TRIM30 α negatively regulates TLR-mediated NF-κB activation by targeting TAB2 and TAB3 for degradation. Nat. Immunol. 9: 369-377. (Pubitemid 351405106)
6. Carty, M., R. Goodbody, M. Schroder, J. Stack, P. N. Moynagh, and A. G. Bowie. 2006. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat. Immunol. 7: 1074-1081. (Pubitemid 44420652)
7. Higgs, R., J. Ni Gabhann, N. Ben Larbi, E. P. Breen, K. A. Fitzgerald, and C. A. Jefferies. 2008. The E3 ubiquitin ligase Ro52 negatively regulates IFN-β production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J. Immunol. 181: 1780-1786.
8. Palsson-McDermott, E. M., S. L. Doyle, A. F. McGettrick, M. Hardy, H. Husebye, K. Banahan, M. Gong, D. Golenbock, T. Espevik, and L. A. O'Neill. 2009. TAG, a splice variant of the adaptor TRAM, negatively regulates the adaptor MyD88-independent TLR4 pathway. Nat. Immunol. 10: 579-586.
9. Xu, H., H. An, J. Hou, C. Han, P. Wang, Y. Yu, and X. Cao. 2008. Phosphatase PTP1B negatively regulates MyD88- and TRIF-dependent proinflammatory cytokine and type I interferon production in TLR-triggered macrophages. Mol. Immunol. 45: 3545-3552.
10. Orr, S. J., N. M. Morgan, R. J. Buick, C. R. Boyd, J. Elliott, J. F. Burrows, C. A. Jefferies, P. R. Crocker, and J. A. Johnston. 2007. SOCS3 targets Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses. J. Biol. Chem. 282: 3418-3422.
11. Orr, S. J., N. M. Morgan, J. Elliott, J. F. Burrows, C. J. Scott, D. W. McVicar, and J. A. Johnston. 2007. CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. Blood 109: 1061-1068.
12. Zhang, M., T. Angata, J. Y. Cho, M. Miller, D. H. Broide, and A. Varki. 2007. Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. Blood 109: 4280-4287. (Pubitemid 46743394)
13. Hoffmann, A., S. Kerr, J. Jellusova, J. Zhang, F. Weisel, U. Wellmann, T. H. Winkler, B. Kneitz, P. R. Crocker, and L. Nitschke. 2007. Siglec-G is a B1 cell-inhibitory receptor that controls expansion and calcium signaling of the B1 cell population. Nat. Immunol. 8: 695-704. (Pubitemid 46965345)
14. Ding, C., Y. Liu, Y. Wang, B. K. Park, C. Y. Wang, P. Zheng, and Y. Liu. 2007. Siglecg limits the size of B1a B cell lineage by down-regulating NFκB activation. PLoS ONE 2(10): e997. (Pubitemid 351479820)
15. Ando, M., W. Tu, K. Nishijima, and S. Iijima. 2008. Siglec-9 enhances IL-10 production in macrophages via tyrosine-based motifs. Biochem. Biophys. Res. Commun. 369: 878-883.
16. Zhang, J. Q., B. Biedermann, L. Nitschke, and P. R. Crocker. 2004. The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur. J. Immunol. 34: 1175-1184.
17. Elliott, J., O. T. Lynch, Y. Suessmuth, P. Qian, C. R. Boyd, J. F. Burrows, R. Buick, N. J. Stevenson, O. Touzelet, M. Gadina, et al. 2007. Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase. J. Virol. 81: 3428-3436. (Pubitemid 46456651)
18. Burrows, J. F., M. J. McGrattan, A. Rascle, M. Humbert, K. H. Baek, and J. A. Johnston. 2004. DUB-3, a cytokine-inducible deubiquitinating enzyme that blocks proliferation. J. Biol. Chem. 279: 13993-14000.
19. Crocker, P. R., J. C. Paulson, and A. Varki. 2007. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7: 255-266.
20. Fitzgerald, K. A., S. M. McWhirter, K. L. Faia, D. C. Rowe, E. Latz, D. T. Golenbock, A. J. Coyle, S. M. Liao, and T. Maniatis. 2003. IKKεand TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4: 491-496.
21. McWhirter, S. M., K. A. Fitzgerald, J. Rosains, D. C. Rowe, D. T. Golenbock, and T. Maniatis. 2004. IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts. Proc. Natl. Acad. Sci. USA 101: 233-238.
22. Ulyanova, T., D. D. Shah, and M. L. Thomas. 2001. Molecular cloning of MIS, a myeloid inhibitory siglec, that binds protein-tyrosine phosphatases SHP-1 and SHP-2. J. Biol. Chem. 276: 14451-14458. (Pubitemid 37391838)
23. Yu, Z., M. Maoui, L. Wu, D. Banville, and S. Shen. 2001. mSiglec-E, a novel mouse CD33-related siglec (sialic acid-binding immunoglobulin-like lectin) that recruits Src homology 2 (SH2)-domain-containing protein tyrosine phosphatases SHP-1 and SHP-2. Biochem. J. 353: 483-492. (Pubitemid 32158316)
24. Salmond, R. J., and D. R. Alexander. 2006. SHP2 forecast for the immune system: fog gradually clearing. Trends Immunol. 27: 154-160. (Pubitemid 43306810)
25. Poole, A. W., and M. L. Jones. 2005. A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell Signal 17: 1323-1332.
26. An, H., W. Zhao, J. Hou, Y. Zhang, Y. Xie, Y. Zheng, H. Xu, C. Qian, J. Zhou, Y. Yu, et al. 2006. SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production. Immunity 25: 919-928. (Pubitemid 44894946)
27. An, H., J. Hou, J. Zhou, W. Zhao, H. Xu, Y. Zheng, Y. Yu, S. Liu, and X. Cao. 2008. Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat. Immunol. 9: 542-550. (Pubitemid 351560523)
28. Diehl, G. E., H. H. Yue, K. Hsieh, A. A. Kuang, M. Ho, L. A. Morici, L. L. Lenz, D. Cado, L. W. Riley, and A. Winoto. 2004. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21: 877-889.
29. Brint, E. K., D. Xu, H. Liu, A. Dunne, A. N. McKenzie, L. A. O'Neill, and F. Y. Liew. 2004. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immunol. 5: 373-379.
30. Wald, D., J. Qin, Z. Zhao, Y. Qian, M. Naramura, L. Tian, J. Towne, J. E. Sims, G. R. Stark, and X. Li. 2003. SIGIRR, a negative regulator of Toll-like receptorinterleukin 1 receptor signaling. Nat. Immunol. 4: 920-927.
31. Lech, M., O. P. Kulkarni, S. Pfeiffer, E. Savarese, A. Krug, C. Garlanda, A. Mantovani, and H. J. Anders. 2008. Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J. Exp. Med. 205: 1879-1888.
32. Piao, W., C. Song, H. Chen, L. M. Wahl, K. A. Fitzgerald, L. A. O'Neill, and A. E. Medvedev. 2008. Tyrosine phosphorylation of MyD88 adapter-like (Mal) is critical for signal transduction and blocked in endotoxin tolerance. J. Biol. Chem. 283: 3109-3119.
33. Jefferies, C. A., S. Doyle, C. Brunner, A. Dunne, E. Brint, C. Wietek, E. Walch, T. Wirth, and L. A. O'Neill. 2003. Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor κB activation by Toll-like receptor 4. J. Biol. Chem. 278: 26258-26264.
34. Kim, Y., P. Zhou, L. Qian, J. Z. Chuang, J. Lee, C. Li, C. Iadecola, C. Nathan, and A. Ding. 2007. MyD88-5 links mitochondria, microtubules, and JNK3 in neurons and regulates neuronal survival. J. Exp. Med. 204: 2063-2074. (Pubitemid 47360869)